Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Twelve-year Retrospective Analysis Of Lung Cancer--The TYROL Study: Daily Routine In 1,424 Patients (1995-2006)

M. Fiegl, W. Hilbe, J. Auberger, T. Schmid, T. Auberger, A. Tzankov, W. Sterlacci, H. Denz, H. Jamnig, R. Greil
Published 2008 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy

This paper is referenced by
Tissue-sparing application of the newly proposed IASLC/ATS/ERS classification of adenocarcinoma of the lung shows practical diagnostic and prognostic impact.
W. Sterlacci (2012)
Detailed assessment of microvasculature markers in non-small cell lung cancer reveals potentially clinically relevant characteristics
G. Pomme (2015)
Gender aspects in haematology and oncology: Overview and own observations in lung cancer
M. Fiegl (2011)
Putative Stem Cell Markers in Non–Small-Cell Lung Cancer: A Clinicopathologic Characterization
W. Sterlacci (2014)
High transforming growth factor β expression represents an important prognostic parameter for surgically resected non-small cell lung cancer.
W. Sterlacci (2012)
The elderly patient with surgically resected non-small cell lung cancer — A distinct situation?
W. Sterlacci (2012)
The need for third-line treatment in non-small cell lung cancer: an overview of new options.
K. Syrigos (2011)
A Comprehensive Analysis of p16 Expression, Gene Status, and Promoter Hypermethylation In Surgically Resected Non-small Cell Lung Carcinomas
W. Sterlacci (2011)
B Cell Lymphoma with Lung Involvement: What Is It about?
M. Mian (2014)
Prognostic factors affecting survival in third-line treatment of advanced non-small cell lung cancer: Retrospective cohort study
Ferit Aslan (2020)
Third-line therapy in the epidermal growth factor receptor mutation-positive advanced nonsmall-cell lung cancer
V. Noronha (2020)
[Fourth-line and beyond therapy in advanced non-small cell lung cancer: a retrospective analysis].
Xianfeng Wang (2014)
Single-agent pegylated liposomal doxorubicin (PLD) in the treatment of metastatic breast cancer: results of an Austrian observational trial
M. Fiegl (2011)
Basic clinical parameters predict gefitinib efficacy in non-small cell lung cancer.
A. Pircher (2011)
Favorable prognosis of operable non-small cell lung cancer (NSCLC) patients harboring an increased expression of tumor endothelial markers (TEMs).
A. Pircher (2013)
The prognostic impact of sex on surgically resected non-small cell lung cancer depends on clinicopathologic characteristics.
W. Sterlacci (2011)
Clinical relevance of neuroendocrine differentiation in non-small cell lung cancer assessed by immunohistochemistry: a retrospective study on 405 surgically resected cases
W. Sterlacci (2009)
Multicenter phase II study evaluating docetaxel and cisplatin as neoadjuvant induction regimen prior to surgery or radiochemotherapy with docetaxel, followed by adjuvant docetaxel therapy in chemonaive patients with NSCLC stage II, IIIA and IIIB (TAX-AT 1.203 Trial).
F. Kocher (2014)
A Comprehensive Analysis of p 16 Expression , Gene Status , and Promoter Hypermethylation In Surgically Resected Non-small Cell Lung Carcinomas
W. Sterlacci (2011)
Deregulation of p27 and Cyclin D1/D3 Control Over Mitosis Is Associated with Unfavorable Prognosis in Non-small Cell Lung Cancer, as Determined in 405 Operated Patients
W. Sterlacci (2010)
Docetaxel in the treatment of non-small cell lung cancer (NSCLC) -- an observational study focusing on symptom improvement.
A. Pircher (2013)
Semantic Scholar Logo Some data provided by SemanticScholar